

# Stephen L Archer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7710654/publications.pdf>

Version: 2024-02-01

167  
papers

24,212  
citations

10389

72  
h-index

7348

152  
g-index

169  
all docs

169  
docs citations

169  
times ranked

19798  
citing authors

#	ARTICLE	IF	CITATIONS
1	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 53, 1573-1619.	2.8	1,797
2	A Mitochondria-K <sup>+</sup> Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth. Cancer Cell, 2007, 11, 37-51.	16.8	1,374
3	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Circulation, 2009, 119, 2250-2294.	1.6	992
4	Pediatric Pulmonary Hypertension. Circulation, 2015, 132, 2037-2099.	1.6	879
5	Mitochondrial Dynamics – Mitochondrial Fission and Fusion in Human Diseases. New England Journal of Medicine, 2013, 369, 2236-2251.	27.0	843
6	Cellular and Molecular Basis of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S20-S31.	2.8	714
7	Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ: British Medical Journal, 2018, 360, j5492.	2.3	553
8	An Abnormal Mitochondrial – Hypoxia Inducible Factor-1 – Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats. Circulation, 2006, 113, 2630-2641.	1.6	530
9	Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility. Circulation, 2007, 116, 238-248.	1.6	486
10	Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D4-D12.	2.8	465
11	Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB Journal, 2012, 26, 2175-2186.	0.5	458
12	The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels. FASEB Journal, 1995, 9, 183-189.	0.5	442
13	Basic Science of Pulmonary Arterial Hypertension for Clinicians. Circulation, 2010, 121, 2045-2066.	1.6	440
14	Acute Oxygen-Sensing Mechanisms. New England Journal of Medicine, 2005, 353, 2042-2055.	27.0	435
15	Hypoxic pulmonary vasoconstriction. Journal of Applied Physiology, 2005, 98, 390-403.	2.5	398
16	Dynamin-Related Protein 1 – Mediated Mitochondrial Mitotic Fission Permits Hyperproliferation of Vascular Smooth Muscle Cells and Offers a Novel Therapeutic Target in Pulmonary Hypertension. Circulation Research, 2012, 110, 1484-1497.	4.5	363
17	Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in Pulmonary Arterial Hypertension. Circulation, 2010, 121, 2661-2671.	1.6	361
18	The Right Ventricle in Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 176-188.	4.5	361

#	ARTICLE	IF	CITATIONS
19	Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2003, 108, 2066-2069.	1.6	341
20	Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats. <i>Circulation</i> , 2002, 105, 244-250.	1.6	340
21	The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 11418-11423.	7.1	332
22	SIRT3 Deacetylates and Activates OPA1 To Regulate Mitochondrial Dynamics during Stress. <i>Molecular and Cellular Biology</i> , 2014, 34, 807-819.	2.3	331
23	Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2005, 115, 1479-1491.	8.2	323
24	Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1 $\alpha$ -Kv1.5 O <sub>2</sub> -sensing pathway at the intersection of pulmonary hypertension and cancer. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 294, H570-H578.	3.2	319
25	Differential Distribution of Electrophysiologically Distinct Myocytes in Conduit and Resistance Arteries Determines Their Response to Nitric Oxide and Hypoxia. <i>Circulation Research</i> , 1996, 78, 431-442.	4.5	294
26	Hypoxic Pulmonary Vasoconstriction. <i>Chest</i> , 2017, 151, 181-192.	0.8	292
27	Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission. <i>FASEB Journal</i> , 2014, 28, 316-326.	0.5	284
28	Diversity in Mitochondrial Function Explains Differences in Vascular Oxygen Sensing. <i>Circulation Research</i> , 2002, 90, 1307-1315.	4.5	279
29	The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. <i>Journal of Molecular Medicine</i> , 2010, 88, 47-60.	3.9	271
30	In Vivo Gene Transfer of the O <sub>2</sub> -Sensitive Potassium Channel Kv1.5 Reduces Pulmonary Hypertension and Restores Hypoxic Pulmonary Vasoconstriction in Chronically Hypoxic Rats. <i>Circulation</i> , 2003, 107, 2037-2044.	1.6	252
31	Endothelium-Derived Hyperpolarizing Factor in Human Internal Mammary Artery Is 11,12-Epoxyeicosatrienoic Acid and Causes Relaxation by Activating Smooth Muscle BK <sub>Ca</sub> Channels. <i>Circulation</i> , 2003, 107, 769-776.	1.6	243
32	Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e15-e43.	5.6	220
33	Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2009, 361, 1864-1871.	27.0	192
34	Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2012, 14, 14.	3.3	187
35	Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e003973.	2.2	187
36	Preferential Expression and Function of Voltage-Gated, O <sub>2</sub> -Sensitive K <sup>+</sup> Channels in Resistance Pulmonary Arteries Explains Regional Heterogeneity in Hypoxic Pulmonary Vasoconstriction. <i>Circulation Research</i> , 2004, 95, 308-318.	4.5	177

#	ARTICLE	IF	CITATIONS
37	PGC1 $\alpha$ -mediated Mitofusin-2 Deficiency in Female Rats and Humans with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 865-878.	5.6	177
38	Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. <i>Journal of Molecular Medicine</i> , 2012, 90, 31-43.	3.9	175
39	Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2015, 131, 1691-1702.	1.6	160
40	Lung <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography for Diagnosis and Monitoring of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 670-679.	5.6	159
41	A Central Role for CD68(+) Macrophages in Hepatopulmonary Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1080-1091.	5.6	158
42	O <sub>2</sub> Sensing in the Human Ductus Arteriosus. <i>Circulation Research</i> , 2002, 91, 478-486.	4.5	154
43	The Role of K <sup>+</sup> Channels in Determining Pulmonary Vascular Tone, Oxygen Sensing, Cell Proliferation, and Apoptosis: Implications in Hypoxic Pulmonary Vasoconstriction and Pulmonary Arterial Hypertension. <i>Microcirculation</i> , 2006, 13, 615-632.	1.8	150
44	Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000183.	3.0	148
45	Metabolism and Bioenergetics in the Right Ventricle and Pulmonary Vasculature in Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 144-152.	1.7	147
46	Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. <i>Journal of Molecular Medicine</i> , 2013, 91, 1185-1197.	3.9	143
47	Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2010, 299, L401-L412.	2.9	142
48	Right Ventricular Adaptation and Failure in Pulmonary Arterial Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 391-406.	1.7	140
49	Impairment of hypoxic pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel Kv1.5. <i>FASEB Journal</i> , 2001, 15, 1801-1803.	0.5	138
50	Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. <i>Journal of Molecular Medicine</i> , 2010, 88, 1011-1020.	3.9	137
51	Differentiating COVID-19 Pneumonia From Acute Respiratory Distress Syndrome and High Altitude Pulmonary Edema. <i>Circulation</i> , 2020, 142, 101-104.	1.6	136
52	Oxygen Activates the Rho/Rho-Kinase Pathway and Induces RhoB and ROCK-1 Expression in Human and Rabbit Ductus Arteriosus by Increasing Mitochondria-Derived Reactive Oxygen Species. <i>Circulation</i> , 2007, 115, 1777-1788.	1.6	135
53	MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 515-529.	5.6	134
54	Hypoxic pulmonary vasoconstriction: redox regulation of O <sub>2</sub> -sensitive K <sup>+</sup> channels by a mitochondrial O <sub>2</sub> -sensor in resistance artery smooth muscle cells. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 1119-36.	1.9	129

#	ARTICLE	IF	CITATIONS
55	FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. <i>Journal of Molecular Medicine</i> , 2013, 91, 333-346.	3.9	125
56	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238.	10.7	122
57	Mitochondrial dynamics in pulmonary arterial hypertension. <i>Journal of Molecular Medicine</i> , 2015, 93, 229-242.	3.9	121
58	Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 138, 287-304.	1.6	115
59	Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. <i>Circulation Research</i> , 2018, 122, 1021-1032.	4.5	111
60	Long-term Effects of Epoprostenol on the Pulmonary Vasculature in Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2010, 138, 1234-1239.	0.8	109
61	GRK2-Mediated Inhibition of Adrenergic and Dopaminergic Signaling in Right Ventricular Hypertrophy. <i>Circulation</i> , 2012, 126, 2859-2869.	1.6	106
62	Oxygen-Sensitive Kv Channel Gene Transfer Confers Oxygen Responsiveness to Preterm Rabbit and Remodeled Human Ductus Arteriosus. <i>Circulation</i> , 2004, 110, 1372-1379.	1.6	101
63	Mitochondrial iron-sulfur clusters: Structure, function, and an emerging role in vascular biology. <i>Redox Biology</i> , 2021, 47, 102164.	9.0	101
64	Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2020, 142, 1464-1484.	1.6	96
65	Voltage-gated potassium channels in human ductus arteriosus. <i>Lancet</i> , 2000, 356, 134-137.	13.7	95
66	Hypoxic fetoplacental vasoconstriction in humans is mediated by potassium channel inhibition. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H2440-H2449.	3.2	91
67	Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension. <i>Journal of Molecular Medicine</i> , 2017, 95, 381-393.	3.9	90
68	Role of Dynamin-Related Protein 1 (Drp1)-Mediated Mitochondrial Fission in Oxygen Sensing and Constriction of the Ductus Arteriosus. <i>Circulation Research</i> , 2013, 112, 802-815.	4.5	88
69	Epigenetic Mechanisms of Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2011, 1, 347-356.	1.7	85
70	Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2020, 126, 1723-1745.	4.5	83
71	Inhibition of the Mitochondrial Fission Protein Dynamin-Related Protein 1 Improves Survival in a Murine Cardiac Arrest Model. <i>Critical Care Medicine</i> , 2015, 43, e38-e47.	0.9	81
72	The role of Drp1 adaptor proteins MiD49 and MiD51 in mitochondrial fission: implications for human disease. <i>Clinical Science</i> , 2016, 130, 1861-1874.	4.3	78

#	ARTICLE	IF	CITATIONS
73	A Proposed Mitochondrialâ€“Metabolic Mechanism for Initiation and Maintenance of Pulmonary Arterial Hypertension in Fawn-Hooded Rats: The Warburg Model of Pulmonary Arterial Hypertension. <i>Advances in Experimental Medicine and Biology</i> , 2010, 661, 171-185.	1.6	78
74	A Placebo-Controlled Trial of Prostacyclin in Acute Respiratory Failure in COPD. <i>Chest</i> , 1996, 109, 750-755.	0.8	77
75	QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. <i>International Journal of Cardiology</i> , 2013, 167, 669-676.	1.7	77
76	Novel Mutations and Decreased Expression of the Epigenetic Regulator <i>TET2</i> in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2020, 141, 1986-2000.	1.6	75
77	Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease. <i>Circulation Research</i> , 2019, 125, 449-466.	4.5	73
78	Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 292, L872-L878.	2.9	72
79	Peripheral Blood Signature of Vasodilator-Responsive Pulmonary Arterial Hypertension. <i>Circulation</i> , 2015, 131, 401-409.	1.6	72
80	Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamycin-atorvastatin-simvastatin study. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 293, L933-L940.	2.9	71
81	Potassium channels and erectile dysfunction. <i>Vascular Pharmacology</i> , 2002, 38, 61-71.	2.1	69
82	Trends and Outcomes of Pulmonary Arterial Hypertensionâ€“Related Hospitalizations in the United States. <i>JAMA Cardiology</i> , 2016, 1, 1021.	6.1	69
83	Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 464-475.	5.6	69
84	Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 376-384.	0.6	68
85	Identification of novel dynaminâ€“related protein 1 (Drp1) GTPase inhibitors: <i>Therapeutic potential of Drpitor1 and Drpitor1a in cancer and cardiac ischemiaâ€“reperfusion injury</i> . <i>FASEB Journal</i> , 2020, 34, 1447-1464.	0.5	68
86	Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance. <i>Nature Cell Biology</i> , 2022, 24, 168-180.	10.3	68
87	Ndufs2, a Core Subunit of Mitochondrial Complex I, Is Essential for Acute Oxygen-Sensing and Hypoxic Pulmonary Vasoconstriction. <i>Circulation Research</i> , 2019, 124, 1727-1746.	4.5	67
88	Redox control of oxygen sensing in the rabbit ductus arteriosus. <i>Journal of Physiology</i> , 2001, 533, 253-261.	2.9	64
89	The Mechanism(s) of Hypoxic Pulmonary Vasoconstriction: Potassium Channels, Redox O <sub>2</sub> Sensors, and Controversies. <i>Physiology</i> , 2002, 17, 131-137.	3.1	62
90	An anesthesiologist's guide to hypoxic pulmonary vasoconstriction: implications for managing single-lung anesthesia and atelectasis. <i>Current Opinion in Anaesthesiology</i> , 2006, 19, 34-43.	2.0	59

#	ARTICLE	IF	CITATIONS
91	Increased Drp1-Mediated Mitochondrial Fission Promotes Proliferation and Collagen Production by Right Ventricular Fibroblasts in Experimental Pulmonary Arterial Hypertension. <i>Frontiers in Physiology</i> , 2018, 9, 828.	2.8	59
92	O <sub>2</sub> sensing in the human ductus arteriosus: redox-sensitive K <sup>+</sup> channels are regulated by mitochondria-derived hydrogen peroxide. <i>Biological Chemistry</i> , 2004, 385, 205-16.	2.5	57
93	Pyruvate Kinase and Warburg Metabolism in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 136, 2486-2490.	1.6	55
94	Home Virtual Visits for Outpatient Follow-Up Stroke Care: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e13734.	4.3	52
95	Riociguat for Pulmonary Hypertension – A Glass Half Full. <i>New England Journal of Medicine</i> , 2013, 369, 386-388.	27.0	51
96	Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. <i>Journal of the American Heart Association</i> , 2019, 8, e011343.	3.7	50
97	Developmental Absence of the O <sub>2</sub> Sensitivity of L-Type Calcium Channels in Preterm Ductus Arteriosus Smooth Muscle Cells Impairs O <sub>2</sub> Constriction Contributing to Patent Ductus Arteriosus. <i>Pediatric Research</i> , 2008, 63, 176-181.	2.3	49
98	Evolving Epidemiology of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 707-709.	5.6	49
99	Colchicine Depolymerizes Microtubules, Increases Junctophilin $\alpha$ , and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	49
100	The role of redox changes in oxygen sensing. <i>Respiratory Physiology and Neurobiology</i> , 2010, 174, 182-191.	1.6	48
101	A maturational shift in pulmonary K <sup>+</sup> channels, from Ca <sup>2+</sup> sensitive to voltage dependent. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1998, 275, L1019-L1025.	2.9	44
102	COUNTERPOINT: HYPOXIC PULMONARY VASOCONSTRICTION IS NOT MEDIATED BY INCREASED PRODUCTION OF REACTIVE OXYGEN SPECIES. <i>Journal of Applied Physiology</i> , 2006, 101, 995-998.	2.5	44
103	Clinical Determinants and Prognostic Implications of Right Ventricular Dysfunction in Pulmonary Hypertension Caused by Chronic Lung Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e011464.	3.7	44
104	Mitochondrial Fission and Fusion in Human Diseases. <i>New England Journal of Medicine</i> , 2014, 370, 1073-1074.	27.0	43
105	Transcriptomic Signature of Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension: Deep Sequencing Demonstrates Mitochondrial, Fibrotic, Inflammatory and Angiogenic Abnormalities. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2730.	4.1	43
106	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. <i>Genome Medicine</i> , 2021, 13, 80.	8.2	43
107	Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 145-155.	0.6	40
108	Mitochondria in the Pulmonary Vasculature in Health and Disease: Oxygen Sensing, Metabolism, and Dynamics. , 2020, 10, 713-765.		39

#	ARTICLE	IF	CITATIONS
109	Rodent Models of Group 1 Pulmonary Hypertension. Handbook of Experimental Pharmacology, 2013, , 105-149.	1.8	37
110	Macrophageâ€NLRP3 Activation Promotes Right Ventricle Failure in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 608-624.	5.6	37
111	Executive Summary of the American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 898-906.	5.6	36
112	Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. Histopathology, 2012, 61, 597-609.	2.9	34
113	Rodent Models of Group 1 Pulmonary Hypertension. Handbook of Experimental Pharmacology, 2013, 218, 105-149.	1.8	34
114	Acquired Mitochondrial Abnormalities, Including Epigenetic Inhibition of Superoxide Dismutase 2, in Pulmonary Hypertension and Cancer: Therapeutic Implications. Advances in Experimental Medicine and Biology, 2016, 903, 29-53.	1.6	33
115	Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer. Free Radical Biology and Medicine, 2021, 170, 150-178.	2.9	32
116	Pulmonary Vasoconstriction, Oxygen Sensing, and the Role of Ion Channels. Chest, 1998, 114, 17S-22S.	0.8	31
117	The making of a physician-scientist--the process has a pattern: lessons from the lives of Nobel laureates in medicine and physiology. European Heart Journal, 2007, 28, 510-514.	2.2	31
118	Pulmonary Pulse Wave Transit Time is Associated with Right Ventricularâ€Pulmonary Artery Coupling in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2016, 6, 576-585.	1.7	30
119	A mitochondrial redox oxygen sensor in the pulmonary vasculature and ductus arteriosus. Pflugers Archiv European Journal of Physiology, 2016, 468, 43-58.	2.8	30
120	Mitochondria in human neutrophils mediate killing of Staphylococcus aureus. Redox Biology, 2022, 49, 102225.	9.0	30
121	Endothelial <i>BMPR2</i> Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2605-2618.	2.4	29
122	Clinical value of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases. American Journal of Physiology - Cell Physiology, 2020, 318, C1-C28.	4.6	26
123	PINK1â€induced phosphorylation of mitofusin 2 at serine 442 causes its proteasomal degradation and promotes cell proliferation in lung cancer and pulmonary arterial hypertension. FASEB Journal, 2021, 35, e21771.	0.5	25
124	A Central Role for Oxygen-Sensitive K <sup>+</sup> Channels and Mitochondria in the Specialized Oxygen-Sensing System. Novartis Foundation Symposium, 2008, , 157-175.	1.1	24
125	Activation of the EGFR/p38/JNK pathway by mitochondrial-derived hydrogen peroxide contributes to oxygen-induced contraction of ductus arteriosus. Journal of Molecular Medicine, 2014, 92, 995-1007.	3.9	24
126	Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-15.	1.7	24



#	ARTICLE	IF	CITATIONS
127	Aetiology and Management of Male Erectile Dysfunction and Female Sexual Dysfunction in Patients with Cardiovascular Disease. <i>Drugs and Aging</i> , 2005, 22, 823-844.	2.7	22
128	Biventricular Increases in Mitochondrial Fission Mediator (MiD51) and Proglycolytic Pyruvate Kinase (PKM2) Isoform in Experimental Group 2 Pulmonary Hypertension-Novel Mitochondrial Abnormalities. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 195.	2.4	22
129	Dexfenfluramine increases pulmonary artery smooth muscle intracellular Ca <sup>2+</sup> , independent of membrane potential. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 277, L662-L666.	2.9	20
130	Mitochondrial dynamics in cardiovascular disease: fission and fusion foretell form and function. <i>Journal of Molecular Medicine</i> , 2015, 93, 225-228.	3.9	20
131	Suppression of Superoxide-Hydrogen Peroxide Production at Site IQ of Mitochondrial Complex I Attenuates Myocardial Stunning and Improves Postcardiac Arrest Outcomes. <i>Critical Care Medicine</i> , 2020, 48, e133-e140.	0.9	20
132	Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension. <i>Hypertension</i> , 2018, 71, 34-55.	2.7	18
133	Excess Protein O-GlcNAcylation Links Metabolic Derangements to Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7278.	4.1	17
134	Blunted Hypoxic Pulmonary Vasoconstriction in Experimental Neonatal Chronic Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 399-406.	5.6	16
135	An epigenetic increase in mitochondrial fission by MiD49 and MiD51 regulates the cell cycle in cancer: <i>i&gt;Diagnostic and therapeutic implications&lt;/i&gt;. <i>FASEB Journal</i>, 2020, 34, 5106-5127.</i>	0.5	16
136	Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Juncophilin-2 to Altered Mitochondrial Metabolism and Right Ventricular Contractility. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008574.	3.9	14
137	Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 276, L213-L219.	2.9	13
138	A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 315, L502-L516.	2.9	13
139	Supraaortic coronary aortic banding improves right ventricular function in experimental pulmonary arterial hypertension in rats by increasing systolic right coronary artery perfusion. <i>Acta Physiologica</i> , 2020, 229, e13483.	3.8	12
140	Aerosol delivery of diethylenetriamine/nitric oxide, a nitric oxide adduct, causes selective pulmonary vasodilation in perinatal lambs. <i>Translational Research</i> , 1999, 134, 419-425.	2.3	11
141	Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2020, 9, e015221.	3.7	11
142	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. <i>Circulation: Heart Failure</i> , 2021, 14, .	3.9	11
143	Providing care for the 99.9% during the COVID-19 pandemic: How ethics, equity, epidemiology, and cost per QALY inform healthcare policy. <i>Healthcare Management Forum</i> , 2020, 33, 239-242.	1.4	9
144	A central role for oxygen-sensitive K <sup>+</sup> channels and mitochondria in the specialized oxygen-sensing system. <i>Novartis Foundation Symposium</i> , 2006, 272, 157-71; discussion 171-5, 214-7.	1.1	9

#	ARTICLE	IF	CITATIONS
145	Pulmonary hypertension begets pulmonary hypertension: mutually reinforcing roles for haemodynamics, inflammation, and cancer-like phenotypes. <i>Cardiovascular Research</i> , 2016, 111, 1-4.	3.8	8
146	Gone fission: an asymptomatic <i>STAT2</i> mutation elongates mitochondria and causes human disease following viral infection. <i>Brain</i> , 2015, 138, 2802-2806.	7.6	7
147	The molecular mechanisms of oxygen-sensing in human ductus arteriosus smooth muscle cells: A comprehensive transcriptome profile reveals a central role for mitochondria. <i>Genomics</i> , 2021, 113, 3128-3140.	2.9	7
148	Evaluation of the Impact of an Echocardiographic Diagnosis of Pulmonary Hypertension on Patient Outcomes. <i>CJC Open</i> , 2020, 2, 328-336.	1.5	6
149	Hemodynamic Characteristics and Outcomes of Pulmonary Hypertension in Patients Undergoing Tricuspid Valve Repair or Replacement. <i>CJC Open</i> , 2021, 3, 488-497.	1.5	6
150	Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	5
151	Measurement of Nitric Oxide and Nitric Oxide Synthase Activity. , 1999, , 163-185.		4
152	Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	4
153	Inhibiting pyruvate kinase muscle isoform 2 regresses group 2 pulmonary hypertension induced by supra-coronary aortic banding. <i>Acta Physiologica</i> , 2022, 234, e13764.	3.8	3
154	Triple-bonded unsaturated fatty acids are redox active compounds. <i>Lipids</i> , 2001, 36, 431-433.	1.7	2
155	Untreated 37-Year-Old Homozygous Familial Hypercholesterolemic Smoker. <i>Circulation</i> , 2006, 113, e777.	1.6	2
156	Comparison of CT contrast blood pool agents for in-vivo 3D angiography using MicroCT. , 2008, , .		1
157	The Right Ventricle. , 2012, , 537-553.		1
158	Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2021, 10, e021518.	3.7	1
159	The comprehensive transcriptome of human ductus arteriosus smooth muscle cells (hDASMC). <i>Data in Brief</i> , 2022, 40, 107736.	1.0	1
160	Using health administrative data to identify patients with pulmonary hypertension: A single center, proof of concept validation study in Ontario, Canada. <i>Pulmonary Circulation</i> , 2022, 12, e12040.	1.7	1
161	Resistance over compliance describes right ventricular afterload better than resistance-compliance time: a friendly amendment. <i>Pulmonary Circulation</i> , 2017, 7, 275-275.	1.7	0
162	A Step Closer to Understanding How Riociguat Results in Remodelling of the Right Ventricle in Chronic Thromboembolic Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1098-1101.	1.7	0

#	ARTICLE	IF	CITATIONS
163	Response by Dunham-Snary and Archer to Letter Regarding Article, "Ndufs2, a Core Subunit of Mitochondrial Complex I, Is Essential for Acute Oxygen-Sensing and Hypoxic Pulmonary Vasoconstriction". Circulation Research, 2019, 125, e35-e36.	4.5	0
164	Scientist on the Spot: Exploring the cause and cure for pulmonary arterial hypertension. Cardiovascular Research, 2021, 117, e82-e83.	3.8	0
165	Left Main Coronary Artery Compression in Pulmonary Arterial Hypertension: Percutaneous Treatment to Improve Symptoms. CJC Open, 2021, 3, 690-692.	1.5	0
166	Anomalous Right Coronary Artery Arising from Distal Left Circumflex Artery. CJC Open, 2021, 4, 112-113.	1.5	0
167	Novel role of Pre-B Cell Colony Enhancing Factor (PBEF) in pulmonary arterial hypertension (PAH). FASEB Journal, 2010, 24, 1023.6.	0.5	0